Q-omics provides the consensus-scored IAH1 profile across patient tissues and cancer cell-line models. IAH1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IAH1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, IAH1 protein abundance shows 23,968 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where IAH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IAH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IAH1 survival associations across molecular data types. IAH1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IAH1 RNA expression–survival associations across cancer types. High IAH1 expression shows unfavorable associations in UVM, ACC, BLCA, LGG, CESC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IAH1 RNA expression.
This table summarizes IAH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for IAH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IAH1 shows higher tumor expression in HNSC, KIRC, BLCA, LIHC, COAD and KIRP. The HNSC box plot shows higher IAH1 RNA expression in tumor versus normal tissue (log2 FC = +1.045, t-test p < 0.001).
This table shows molecular features associated with IAH1 in patient tissues and cancer cell lines. In patient samples, IAH1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, IAH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
